The iconic rise of Viagra has firmly established as a example of pharmaceutical success, yet its future within the broader industry now triggers questions about long-term yields . Copycat versions are eroding patent protection , leading to concerns that supporting companies heavily reliant to Viagra's former influence could be a problematic move ,